5-chloro-3-methyl-2,4(1H,3H)-quinazolinedione | 118470-98-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-chloro-3-methyl-2,4(1H,3H)-quinazolinedione
• 英文别名: 5-chloro-3-methyl-1H-quinazoline-2,4-dione
• CAS: 118470-98-7
• 化学式: C₉H₇ClN₂O₂
• 分子量: 210.62
• InChiKey: MALRRQSYXWVSJR-UHFFFAOYSA-N

物化性质

• 熔点：
  226-229 °C
• 密度：
  1.420±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-chloro-3-methyl-2,4(1H,3H)-quinazolinedione 在 硫酸 、 硝酸 作用下， 以84%的产率得到5-chloro-3-methyl-6-nitro-2,4(1H,3H)-quinazolinedione
  参考文献：
  名称：

  Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists

  摘要：

  The linear and proximal benzo-separated derivatives of 8-phenyltheophylline, 1,3-diethyl-8-phenylxanthine, 1,3-dipropylxanthine, 1,3-dibutylxanthine, 3-isobutyl-1-methylxanthine, theophylline, caffeine, and isocaffeine have been synthesized and evaluated for affinity at the A1 and A2 adenosine receptors. Although structure-activity relationships in the benzo-separated series differed from the relationships in the simple xanthines, the most potent of the benzo-separated xanthines were about equal in affinity to the most potent of the corresponding xanthines. On the basis of the present results and the diverse structures reported in the literature as non-xanthine adenosine antagonists, it appears that the primary requirement for adenosine-receptor affinity in nonnucleosides is a flat, neutral, fused-ring heterocycle and that once this requirement is met there are numerous potential binding modes.

  DOI：

  10.1021/jm00130a004
• 作为产物：
  描述：

  3-氯-2-甲基苯胺 在 盐酸 、 potassium permanganate 、 magnesium sulfate 、 三乙胺 作用下， 以 甲醇 、 乙醚 、 甲苯 为溶剂， 反应 27.5h， 生成 5-chloro-3-methyl-2,4(1H,3H)-quinazolinedione
  参考文献：
  名称：

  Linear and proximal benzo-separated alkylated xanthines as adenosine-receptor antagonists

  摘要：

  The linear and proximal benzo-separated derivatives of 8-phenyltheophylline, 1,3-diethyl-8-phenylxanthine, 1,3-dipropylxanthine, 1,3-dibutylxanthine, 3-isobutyl-1-methylxanthine, theophylline, caffeine, and isocaffeine have been synthesized and evaluated for affinity at the A1 and A2 adenosine receptors. Although structure-activity relationships in the benzo-separated series differed from the relationships in the simple xanthines, the most potent of the benzo-separated xanthines were about equal in affinity to the most potent of the corresponding xanthines. On the basis of the present results and the diverse structures reported in the literature as non-xanthine adenosine antagonists, it appears that the primary requirement for adenosine-receptor affinity in nonnucleosides is a flat, neutral, fused-ring heterocycle and that once this requirement is met there are numerous potential binding modes.

  DOI：

  10.1021/jm00130a004

文献信息

• Tricyclic heterocyclic compounds and their use in treating benzodiazepin
  申请人：A/S Ferrosan

  公开号：US04902686A1

  公开（公告）日：1990-02-20

  New heterocyclic compounds having the general formula ##STR1## wherein R.sup.3 is ##STR2## CO.sub.2 R' or CONR'R", wherein R' and R" independently are C.sub.1-6 -alkyl, C.sub.3-7 -cycloalkyl or C.sub.1-6 -alkoxymethyl; --A-- is --C(.dbd.O)--NR'"--, --NR'"--C(.dbd.O)--, or ##STR3## wherein R'" is C.sub.1-6 -alkyl; X is C or N; and R.sup.4 is hydrogen, halogen, CN, C.sub.1-6 -alkyl, C.sub.1-6 -alkynyl, trimethylsilyl-C.sub.1-6 -alkynyl, aryloxy which may be substituted with halogen, aralkoxy, C.sub.3-7 -cycloalkoxy which may be substituted with one or more C.sub.1-6 -alkyl groups, or NR""R'"", wherein R"" and R""' independently are C.sub.1-6 -alkyl or together with the nitrogen atom form a 3-7 membered heterocyclic ring. The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and nootropics.

  新的杂环化合物具有一般式##STR1##其中R.sup.3是##STR2## CO.sub.2 R'或CONR'R"，其中R'和R"分别是C.sub.1-6-烷基，C.sub.3-7-环烷基或C.sub.1-6-烷氧甲基; --A--是--C(.dbd.O)--NR'"--，--NR'"--C(.dbd.O)--或##STR3##其中R'"是C.sub.1-6-烷基; X是C或N; R.sup.4是氢，卤素，CN，C.sub.1-6-烷基，C.sub.1-6-炔基，三甲基硅基-C.sub.1-6-炔基，芳氧基，可能带有卤素取代的芳基氧基，芳基烷氧基，可能带有一个或多个C.sub.1-6-烷基基团取代的C.sub.3-7-环烷氧基，或NR""R'"，其中R""和R""'分别是C.sub.1-6-烷基或与氮原子结合形成3-7成员杂环环。这些化合物在心理药物制剂中作为抗癫痫药，抗焦虑药，催眠药和脑力药物有用。
• 3-substituted-4,5-dihydro-5-oxo imidazoquinazolines, their preparation,
  申请人：A/S Ferrosan

  公开号：US04780539A1

  公开（公告）日：1988-10-25

  New heterocyclic compounds having the general formula ##STR1## wherein X is ##STR2## or CO.sub.2 R' wherein R' is C.sub.1-6 -alkyl, C.sub.3-7 -cycloalkyl, or C.sub.3-7 -cycloalkymethyl, R.sup.6 and R.sup.7 independently are hydrogen, halogen, alkoxy, or trifluoromethyl, and R" hydrogen, C.sub.1-6 -alkyl, or C.sub.3-7 -cycloalkyl. The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and nootropics.

  新的杂环化合物具有一般式##STR1##其中X为##STR2##或CO.sub.2R'，其中R'为C.sub.1-6-烷基，C.sub.3-7-环烷基或C.sub.3-7-环烷基甲基，R.sup.6和R.sup.7独立地为氢，卤素，烷氧基或三氟甲基，而R"为氢，C.sub.1-6-烷基或C.sub.3-7-环烷基。这些化合物在精神药理制剂中作为抗癫痫、抗焦虑、催眠药和智能药物有用。
• Tricyclic heterocyclic compounds as psychopharmaceuticals
  申请人：A/S Ferrosan

  公开号：US04873244A1

  公开（公告）日：1989-10-10

  New heterocyclic compounds having the general formula ##STR1## wherein ##STR2## CO.sub.2 R' or CONR'R", wherein R' and R" independently are C.sub.1-6 -alkyl, C.sub.3-7 -cycloalkyl or C.sub.1-6 -alkoxymethyl; --A-- is --C(.dbd.O)--NR'"--, --NR'"--C(.dbd.O)--, or ##STR3## wherein R'" is C.sub.1-6 -alkyl; X is C or N; and R.sup.4 is hydrogen, halogen, CN, C.sub.1-6 -alkyl, C.sub.1-6 -alkynyl, trimethylsilyl-C.sub.1-6 -alkynyl, aryloxy which may be substituted with halogen, aralkoxy, C.sub.3-7 -cycloalkoxy which may be substituted with one or more C.sub.1-6 -alkyl groups, or NR""R'"", wherein R"" and R'"" independently are C.sub.1-6 -alkoxy or together with the nitrogen atom form a 3-7 membered heterocyclic ring. The compounds are useful in psychopharmaceutical preparations as anticonvulsants, anxiolytics, hypnotics, and nootropics.

  一种新的杂环化合物，其通用式为##STR1##其中##STR2##CO.sub.2R'或CONR'R"，其中R'和R"分别是C.sub.1-6-烷基，C.sub.3-7-环烷基或C.sub.1-6-烷氧甲基; --A--为--C(.dbd.O)--NR'"--，--NR'"--C(.dbd.O)--，或##STR3##其中R'"是C.sub.1-6-烷基; X为C或N; R.sup.4为氢，卤素，CN，C.sub.1-6-烷基，C.sub.1-6-炔基，三甲基硅基C.sub.1-6-炔基，可能被卤素取代的芳氧基，芳基氧基，可能被一个或多个C.sub.1-6-烷基取代的C.sub.3-7-环烷氧基或NR""R'"，其中R""和R'""分别是C.sub.1-6-烷氧基或与氮原子一起形成3-7成员的杂环环。这些化合物在心理药物制剂中作为抗惊厥剂，抗焦虑剂，催眠剂和智能药物有用。
• Heterocyclic compounds and their preparation and use
  申请人：A/S FERROSAN

  公开号：EP0226282A2

  公开（公告）日：1987-06-24

  New heterocyclic compounds having the general formula wherein wherein R' is C1-6-alkyl, C3-7-cycloalkyl, or C3-7-cyclo­alkylmethyl, R⁶ and R⁷ independently are hydrogen, halogen, alkoxy or tri­fluoromethyl , and R'' is hydrogen, C1-6-alkyl, or C3-7-cycloalkyl The compounds are useful in psychopharmaceutical preparati­ons as anticonvulsants, anxiolytics, hypnotics, and nootro­pics.

  通式如下的新杂环化合物 其中 其中 R'是 C1-6-烷基、C3-7-环烷基或 C3-7-环烷基甲基、 R⁶ 和 R⁷ 分别为氢、卤素、烷氧基或三氟甲基，以及 R'' 是氢、C1-6-烷基或 C3-7-Cycloalkyl 这些化合物在精神药物制剂中可用作抗惊厥药、抗焦虑药、催眠药和促智药。
• Oxadiazolylacetonitriles, their preparation and use
  申请人：NOVO NORDISK A/S

  公开号：EP0274009A1

  公开（公告）日：1988-07-13

  Compounds of the formulae Compounds of the formulae

  式中化合物 式中化合物 式中化合物 式中化合物